Sugar-coated CAR T for sweeter cell therapies.

Area of Science:

• Immunology
• Cell Biology
• Biochemistry

Background:

• Chimeric antigen receptor (CAR) T cell therapy is a promising cancer treatment.
• Allogeneic CAR T cells offer potential advantages over autologous CAR T cells.
• Enhancing the persistence of allogeneic CAR T cells is critical for sustained therapeutic effects.

Purpose of the Study:

• To investigate the role of the SPPL3 sheddase in regulating CAR T cell function.
• To determine if deleting SPPL3 can improve allogeneic CAR T cell persistence and efficacy.

Main Methods:

• Utilized CRISPR/Cas9 gene editing to delete the SPPL3 gene in T cells.
• Generated allogeneic CAR T cells lacking SPPL3.
• Assessed CAR T cell persistence in vitro and in vivo models.
• Measured CAR T cell proliferation, cytokine production, and cytotoxic activity.

Main Results:

• Deletion of SPPL3 significantly enhanced the persistence of allogeneic CAR T cells.
• SPPL3-deficient CAR T cells exhibited improved survival and reduced susceptibility to activation-induced cell death.
• In vivo studies demonstrated prolonged presence and enhanced anti-tumor activity of SPPL3-deleted CAR T cells.

Conclusions:

• SPPL3 acts as a negative regulator of allogeneic CAR T cell persistence.
• Targeting SPPL3 is a viable strategy to improve the therapeutic potential of allogeneic CAR T cell therapy.
• This finding opens new avenues for engineering more robust CAR T cell products.